Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Glycyrrhizic Acid→

Glycyrrhizic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1405-86-3
Molecular formula
C42H62O16
Molecular weight
822.9 g/mol
Drug class
Triterpenoid saponinlicorice-derived anti-inflammatory and hepatoprotective constituent
Mechanism of action
Glycyrrhizic acid is metabolised to glycyrrhetinic acid and related metabolites. Proposed activities include modulation of HMGB1 and NF-kB signalling, anti-inflammatory and antioxidant effects, membrane stabilisation and modulation of cortisol metabolism. These actions depend on formulation and metabolism; the compound can also cause mineralocorticoid-like adverse effects through inhibition of 11β-hydroxysteroid dehydrogenase.
Indications / reported uses
  • Used as an active constituent in certain licorice-derived hepatoprotective and anti-inflammatory preparations in some jurisdictions; exact indications are formulation- and jurisdiction-specific. It is not a stand-alone universal treatment for liver disease.

Sources: https://pubmed.ncbi.nlm.nih.gov/41789596/ · https://pubmed.ncbi.nlm.nih.gov/42147312/ · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/diammonium-glycyrrhizinate · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Glycyrrhizic Acid Environmental Risk Assessment (ERA) (the Glycyrrhizic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.